Literature DB >> 23288576

The immune pathogenesis of scleroderma: context is everything.

Matthew B Greenblatt1, Antonios O Aliprantis.   

Abstract

The fundamental mechanisms that drive the pathogenesis of systemic sclerosis (SSc) remain elusive, despite over 50 years of investigation. Here, we review recent progress in the understanding of the immunopathogenesis of SSc. In particular, we consider interleukin-13 (IL13), and its upstream and downstream pathways, as an example of an immune system-derived mediator involved in fibrotic and vascular pathology. Emerging results linking pattern-recognition receptors and interferon pathways to SSc are also stressed. We discuss genetic data linking the immune system to SSc risk and efforts to apply animal models to subsets of patients recently resolved by gene expression profiling. These developments will help build a context for better understanding of previous observations and design of the next generation of studies that may eventually lead to effective treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23288576      PMCID: PMC3539168          DOI: 10.1007/s11926-012-0297-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  90 in total

1.  A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations.

Authors:  Lara Bossini-Castillo; Jose-Ezequiel Martin; Jasper Broen; Olga Gorlova; Carmen P Simeón; Lorenzo Beretta; Madelon C Vonk; Jose Luis Callejas; Ivan Castellví; Patricia Carreira; Francisco José García-Hernández; Mónica Fernández Castro; Marieke J H Coenen; Gabriela Riemekasten; Torsten Witte; Nicolas Hunzelmann; Alexander Kreuter; Jörg H W Distler; Bobby P Koeleman; Alexandre E Voskuyl; Annemie J Schuerwegh; Øyvind Palm; Roger Hesselstrand; Annika Nordin; Paolo Airó; Claudio Lunardi; Raffaella Scorza; Paul Shiels; Jacob M van Laar; Ariane Herrick; Jane Worthington; Christopher Denton; Filemon K Tan; Frank C Arnett; Sandeep K Agarwal; Shervin Assassi; Carmen Fonseca; Maureen D Mayes; Timothy R D J Radstake; Javier Martin
Journal:  Hum Mol Genet       Date:  2011-11-10       Impact factor: 6.150

2.  Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling.

Authors:  Michael O Daines; Yasuhiro Tabata; Bradley A Walker; Weiguo Chen; Manoj R Warrier; Saswata Basu; Gurjit K Khurana Hershey
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 3.  Alternative activation of macrophages: an immunologic functional perspective.

Authors:  Fernando O Martinez; Laura Helming; Siamon Gordon
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

4.  Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.

Authors:  Mélanie Pichery; Emilie Mirey; Pascale Mercier; Emma Lefrancais; Arnaud Dujardin; Nathalie Ortega; Jean-Philippe Girard
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

5.  IL13RA2 gene polymorphisms are associated with systemic sclerosis.

Authors:  Brigitte Granel; Yannick Allanore; Christophe Chevillard; Violaine Arnaud; Sandrine Marquet; Pierre-Jean Weiller; Jean-Marc Durand; Jean-Robert Harlé; Claire Grange; Yves Frances; Philippe Berbis; Jean Gaudart; Philippe de Micco; André Kahan; Alain Dessein
Journal:  J Rheumatol       Date:  2006-09-15       Impact factor: 4.666

6.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

7.  HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans.

Authors:  Xiaodong Zhou; Jong Eun Lee; Frank C Arnett; Momiao Xiong; Min Young Park; Yeon Kyeong Yoo; Eun Soon Shin; John D Reveille; Maureen D Mayes; Jin Hyun Kim; Ran Song; Ji Yong Choi; Ji Ah Park; Yun Jong Lee; Eun Young Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Arthritis Rheum       Date:  2009-12

8.  Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems.

Authors:  B D Jaffee; H N Claman
Journal:  Cell Immunol       Date:  1983-04-01       Impact factor: 4.868

9.  Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.

Authors:  Patrizia Fuschiotti; Thomas A Medsger; Penelope A Morel
Journal:  Arthritis Rheum       Date:  2009-04

10.  Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response.

Authors:  Monica G Chiaramonte; Margaret Mentink-Kane; Bruce A Jacobson; Allen W Cheever; Matthew J Whitters; Mary E P Goad; Anthony Wong; Mary Collins; Debra D Donaldson; Michael J Grusby; Thomas A Wynn
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  22 in total

1.  Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.

Authors:  Aniko Rentka; Jolan Harsfalvi; Gabriella Szucs; Zoltan Szekanecz; Peter Szodoray; Krisztina Koroskenyi; Adam Kemeny-Beke
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

Review 2.  Update on macrophages and innate immunity in scleroderma.

Authors:  Jennifer J Chia; Theresa T Lu
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

3.  Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels.

Authors:  Serena Vettori; Giovanna Cuomo; Michele Iudici; Virginia D'Abrosca; Veronica Giacco; Giusi Barra; Raffaele De Palma; Gabriele Valentini
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

Review 4.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

Review 5.  Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.

Authors:  Xiao-Lei Huang; Yu-Jie Wang; Jun-Wei Yan; Ya-Nan Wan; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflamm Res       Date:  2015-03-01       Impact factor: 4.575

6.  Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.

Authors:  Serena Vettori; Salvatore Tolone; Domenico Capocotta; Rossella Chieffo; Veronica Giacco; Gabriele Valentini; Ludovico Docimo
Journal:  Clin Rheumatol       Date:  2018-02-13       Impact factor: 2.980

7.  IL-4 and CCR7 play an important role in the development of keloids in patients with a family history.

Authors:  Mengjie Shan; Hao Liu; Yan Hao; Tian Meng; Cheng Feng; Kexin Song; Youbin Wang
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

8.  The IL-33 gene is related to increased susceptibility to systemic sclerosis.

Authors:  Suleyman Serdar Koca; Yavuz Pehlivan; Murat Kara; Fatma Alibaz-Oner; Serdar Oztuzcu; Neslihan Yilmaz; Gozde Yildirim Cetin; Bunyamin Kisacik; Metin Ozgen; Omer Nuri Pamuk; Haner Direskeneli; Mehmet Sayarlioglu; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2016-01-07       Impact factor: 2.631

Review 9.  The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.

Authors:  Julie K Nguyen; Evan Austin; Alisen Huang; Andrew Mamalis; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2019-09-06       Impact factor: 3.017

10.  Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.

Authors:  Shuo Liu; Melody P Chung; Brett Ley; Sarah French; Brett M Elicker; David F Fiorentino; Lorinda S Chung; Francesco Boin; Paul J Wolters
Journal:  Thorax       Date:  2021-07-16       Impact factor: 9.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.